Shots:
- Enodia has acquired Kezar’s Sec61-based discovery & development program assets, strengthening its understanding of Sec61 selectivity mechanisms & expanding translational insights to accelerate progress toward key clinical milestones
- As per the deal, Kezar will receive a $1M upfront, ~$127M in development, regulatory, & commercial milestones, plus tiered royalties on future net sales
- Enodia’s platform selectively modulates the Sec61 Translocon to block disease-relevant proteins during synthesis while preserving normal functions; insights from Kezar’s Sec61 programs will further enhance this targeted protein-degradation approach
Ref: Businesswire | Image: Enodia & Kezar | Press Release
Related News: PRISM BioLab and Receptor.AI Partner to Develop a Drug Discovery Platform
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
